Check for updates

CLINICAL PRACTICE ARTICLE

Management of thrombocythemia [version 1; peer review: 2 approved]

Krisstina Gowin¹, Ruben Mesa²¹Department of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, AZ, 85259, USA²Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, AZ, 85259, USA

V1 First published: 29 Sep 2014, 3:227
<https://doi.org/10.12688/f1000research.5361.1>
Latest published: 29 Sep 2014, 3:227
<https://doi.org/10.12688/f1000research.5361.1>

Abstract

Essential thrombocythemia is a clonal myeloproliferative neoplasm characterized by an elevated platelet count, the potential for both microvascular and macrovascular sequelae, and a risk for transformation to myelofibrosis or acute myeloid leukemia. A systematic and detailed initial analysis is essential for accurate diagnosis of essential thrombocythemia, as many etiologies are reactive and benign. Once a diagnosis has been made, risk stratification and symptom assessment are vital to guide the subsequent therapy. Treatment may be required in high-risk disease, such as in cases of advanced age or prior thrombotic events. Systemic therapy is aimed at reducing the thrombotic risk and includes daily low dose aspirin and in some patients, cytoreductive therapy. Currently, the first line cytoreductive therapy includes hydroxyurea or pegylated interferon, with a phase III clinical trial underway comparing these two important agents. Anagrelide and clinical trials are reserved for refractory or intolerant patients. Looking to the future, new therapies including Janus kinase 2 (JAK2) and telomerase inhibitors are promising and may become valuable to the treatment armamentarium for those afflicted with essential thrombocythemia.

Keywords

Thrombocythemia, Janus kinase 2, cytoreductive therapy

Open Peer Review

Approval Status

	1	2
version 1 29 Sep 2014	view	view

1. **Laura C. Michaelis**, Medical College of Wisconsin, Froedtert Hospital, Milwaukee, USA
2. **Ann Mullally**, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Ruben Mesa (mesa.ruben@mayo.edu)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2014 Gowin K and Mesa R. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Gowin K and Mesa R. **Management of thrombocythemia [version 1; peer review: 2 approved]** F1000Research 2014, 3:227 <https://doi.org/10.12688/f1000research.5361.1>

First published: 29 Sep 2014, 3:227 <https://doi.org/10.12688/f1000research.5361.1>

Introduction

Thrombocythemia, or elevation in platelet count (i.e. greater than $450 \times 10^9/L$), is a common observation for internists and hematologists alike. Causes may be secondary or “acquired” in contrast to primary thrombocythemia, meaning that the pathogenesis lies within the abnormal marrow itself. Essential thrombocythemia (ET), one of the myeloproliferative neoplasms (MPNs), is an aberration within the bone marrow and its microenvironment leading to clonal proliferation of the megakaryocytic lineage within the marrow and, ultimately, to peripheral blood thrombocythemia. Unlike secondary thrombocythemia, ET is associated with thrombotic and hemorrhagic complications and requires systemic medical therapy in high-risk patients. In this brief article, we discuss the diagnostic strategy of thrombocytosis with particular attention paid to essential thrombocythemia. Subsequently, the clinical manifestations of ET are examined and the assessment of disease burden is reviewed. The history of therapeutics for ET is reviewed with consideration to the current rationale for therapeutic decision-making.

Uncovering the etiology

Elucidating the etiology of thrombocythemia is of utmost importance prior to any therapeutic decision-making. Certainly, clonal bone marrow diseases such as MPNs should be considered. However, such a diagnosis can only be considered after eliminating secondary contributions to the elevated platelet count. Many chronic and acute processes cause stimulation and up-regulation of bone marrow stem cells including infection, malignancy, iron deficiency, prior splenectomy, and recent trauma or surgery. (see Table 1). A careful examination of iron status, inflammatory markers, and age appropriate malignancy screen is imperative. History and physical exam, such as a history of gastrointestinal bleeding, rheumatologic disease or the presence of splenomegaly on exam can lend clues as to underlying etiologies. Once secondary causes are excluded, evaluation for an underlying clonal myeloproliferative disorder can commence.

Establishing a diagnosis

MPNs such as ET, polycythemia vera (PV), and myelofibrosis (MF) are Philadelphia negative clonal disorders of the bone marrow¹. When attempting to establish a diagnosis of MPN, mutational status can be quite helpful². In 2005, a landmark discovery identified a gain of function mutation, *JAKV617F*, as being an essential mutational driver in many MPNs³⁻⁵. In ET, approximately 50% of patients will harbor the *JAKV617F* mutation. PCR based assays for the JAK2 mutation, from either peripheral blood or marrow, are commercially available. Since the *JAKV617F* discovery, other molecular breakthroughs have contributed not only to our knowledge of pathogenesis in MPNs but also how we diagnose them. In the majority of *JAKV617F* wild type patients, the *CALR* (calreticulin gene) mutation⁶ may be detected and now is a widely available assay. Additionally, *MPL* (myeloproliferative leukemia gene) mutations are detected in a small percentage (<5%) of those afflicted with ET^{7,8}. Although mutation analysis is critical for the evaluation of a suspected MPN, it is not sufficient for diagnosis. A bone marrow biopsy must be obtained and possess features consistent with ET, such as megakaryocytic hyperplasia. Additionally, assessment of cytogenetics, baseline karyotype, reticulin fibrosis, and blast percentage should be performed. Mutational status for other myeloid

diseases must be evaluated and negative including the *BCR-ABL*, i.e. “the Philadelphia chromosome”, and fluorescence in situ hybridization (FISH) for myelodysplastic syndrome (MDS) panel to exclude the diagnosis of CML and MDS, respectively (see Table 2)².

Assessing symptom burden

The presentation of MPN may be quite variable. A large proportion of those afflicted with ET are completely asymptomatic at presentation. Unfortunately, approximately 50% of patients with ET do possess some form of systemic manifestation of the disease and experience a substantial impact on their quality of life⁹. Common symptoms may include those from microvascular complications such as headache, dizziness, paresthesia, livedo reticularis, erythromelalgia, and visual changes. Others may present with the more dreaded macrovascular complications such as myocardial infarction, stroke, or pulmonary embolus. Additionally, constitutional symptoms may be prevalent with symptoms of fatigue, night sweats, and weight loss; particularly in those transitioning to a more

Table 1. Causes of thrombocythemia.

Secondary thrombocythemia	<ul style="list-style-type: none">– Infection– Post surgical status, particularly orthopedic procedures– Malignancy– Post Splenectomy– Iron deficiency– Hemolytic anemia– B12 deficiency– Immune thrombocytopenia purpura (ITP) rebound effect– Severe burns– Rheumatologic disorders: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), celiac sprue– Medications
Primary thrombocythemia	<ul style="list-style-type: none">– Philadelphia negative myeloproliferative neoplasms (PV, ET, MF)– Chronic Myeloid Leukemia (CML)– Chronic Myelomonocytic Leukemia (CMML)– Myelodysplastic syndrome (MDS) and MPN overlap syndrome

Table 2. WHO 2008 criteria for essential thrombocythemia (ET)².

Diagnosis requires meeting ALL 4 criteria:
<ol style="list-style-type: none">1. Sustained platelet count $\geq 450 \times 10^9/L$2. Bone marrow biopsy showing proliferation mainly of megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes. No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis.3. No meeting WHO criteria for polycythemia vera, primary myelofibrosis, <i>BCR-ABL</i> positive CML, MDS, or other myeloid neoplasm.4. Demonstration of <i>JAK2 V617F</i> or other clonal marker, or in the absence of <i>JAK2 V617F</i>, no evidence of reactive thrombocytosis.

myelofibrotic state. In 2007, a group of researchers set out to create and validate a symptom assessment tool specific to the MPN population¹⁰. Due to this effort, the MPN-Symptom Assessment Form (SAF)¹¹ is now available and validated for use in this patient population and has proven to be an invaluable tool in the assessment and management of ET. Though use of the MPN-SAF a subset of ET patients were identified who possess a significant symptomatic burden, with fatigue and microvascular complications being the most prevalent¹⁰. For the treating clinician, the MPN-SAF can be utilized to assess baseline symptomatology and help guide initial therapeutic decision-making as well as gauge subsequent response to therapy.

Risk assessment

Deciding when to initiate therapy in ET may be complex and represents a unique challenge in the treatment of MPNs. A thrombotic risk assessment is necessary to evaluate whether initiation of cytoreduction is warranted^{12,13}. The presence of high-risk features¹⁴, such as age greater than 60 years and a prior history of thrombosis, is predictive of future complications and generally prompts the clinician to employ cytoreduction. Additionally, concurrent cardiovascular risk factors¹⁵, *JAK V617F* mutational status and allelic burden^{16,17}, and the presence of leukocytosis¹⁸ may increase the thrombotic risk potential and contribute to a clinician's decision to initiate therapy. The presence of a heavy symptom burden may also provide more impetus to employ cytoreduction in afflicted patients who are otherwise in a low risk category. An international prognostic model for ET was developed in 2012 by Passamonti *et al.* and is helpful to ascertain risk and give valuable prognostic information to the treating physician (see Table 3)¹³. The treatment goal is improvement in disease related symptoms in addition to normalization of the platelet count to decrease thrombotic risk potential. Typically, the minimal effective dose is utilized to limit treatment-associated toxicity. In those with low-risk asymptomatic disease, simple observation is appropriate.

Initial systemic therapy

In 2004, a European group investigated the use of aspirin for the prevention of thrombotic complications in PV and found that daily low dose aspirin can safely prevent thrombotic complications in those who have no contraindications to such treatment¹⁹. Since this landmark study, it is standard practice to administer daily low dose aspirin to all those with high-risk ET. In those with very high initial platelet counts, greater than 1,500/microL, an acquired Von Willebrand deficit may occur and increase risk for hemorrhagic complications. Because of this, some practitioners may elect to cytoreduce prior to aspirin initiation. Currently, first line cytoreductive

therapy is a choice amongst three agents: hydroxyurea, anagrelide, and pegylated interferon. Fortunately, recent trials have clarified some therapeutic nuances of each choice. Hydroxyurea is a traditional treatment for preventing thrombosis in ET since Cortelazzo published on its efficacy in 1995²⁰. Later, anagrelide was approved for control of thrombocytosis based on single arm studies²¹. Subsequently, a conundrum was raised as to which agent was superior and preferential in first line therapy. In 2005, Harrison *et al.* sought to answer this with a randomized comparison of hydroxyurea to anagrelide²². In this study, hydroxyurea was found to be superior to anagrelide in terms of rate of arterial thrombosis, serious hemorrhage, and transformation to myelofibrosis, but was inferior in terms of rates of venous thrombosis. Consequently, hydroxyurea became standard first line therapy, with anagrelide being reserved for second line treatment. In 2008, pegylated interferon, a more tolerable form of interferon, was demonstrated to induce hematologic and molecular responses in ET^{23,24}. As an added benefit, pegylated interferon has been shown to retard progression towards fibrosis in some studies^{25,26} however this remains controversial and is an area of ongoing investigation. Currently, it is still unknown whether hydroxyurea or pegylated interferon represents the best initial treatment strategy. The Myeloproliferative Disorders Research Consortium (MPD-RC) is conducting a phase III international study to evaluate the efficacy, safety, and tolerability of hydroxyurea versus pegylated interferon in frontline therapy for ET/PV. (clinicaltrials.gov: NCT01259817). Additionally, it is important to mention that interferon therapy is safe in pregnancy, unlike hydroxyurea and anagrelide and thus, pegylated interferon is the preferred agent in this patient population or those who wish to become pregnant.

Second line therapy

In those who are intolerant or resistant to initial therapy a therapeutic switch is indicated and is largely guided by first line choices. A common practice is to progress through the first line cytoreductive agents, with no data directing the sequence of therapies. Aspirin is continued throughout if not contraindicated. The duration of therapy is typically lifelong, with the goal of treatment being hemorrhagic and thrombotic risk reduction, as well as retardation of disease progression. For those who are intolerant to or progressed on all approved agents, clinical trials should be considered. Novel therapeutics, particularly JAK inhibitors, offer a valuable addition to the treatment armamentarium and are available via clinical trial for ET. Moreover, other drug classes such as telomerase inhibitors are promising for the future treatment of ET. Often, in those with very proliferative disease (i.e. platelet count >2000 × 10⁹/L), an effective combination therapeutic approach is used. Hydroxyurea and anagrelide, for example, can be used concurrently for optimal cytoreduction and greater tolerability, as the dosage of each is lower in combination than with single agent therapy alone.

Monitoring for progression

A minority of patients progress to myelofibrosis or acute myeloid leukemia (AML)²⁷. Practitioners should pay careful attention to the patient's symptom burden, peripheral blood counts, and cytogenetic analysis for clues indicating progression. The development of increased constitutional symptoms such as progressive splenomegaly, fever, weight loss, early satiety, and bone pain in conjunction with a trend towards either new cytopenia or increased rate of

Table 3. Essential thrombocythemia risk assessment per IPSET¹³.

Prognostic features in ET	<ul style="list-style-type: none"> – Age >60 years (2 points) – Prior history of thrombosis (1 point) – Leukocytes >11 × 10⁹/L (1 point)
Risk group:	
0: Low	
1-2: Intermediate	
3-4: High	

proliferative disease increases clinical suspicion of a post ET-myelofibrosis. Conversely, those with new blasts on peripheral smear and/or marrow and new cytogenetic complexity should be evaluated for MPN blast phase or AML²⁸.

Conclusion

In evaluating cases of thrombocythemia, it is essential to exclude both reactive processes and other chronic myeloid disorders prior to making the diagnosis of essential thrombocythemia. Mutational analysis is helpful in making the diagnosis and the well-informed clinician can consider *JAKV617F* and if wild type subsequent *MPL*, and *CALR* assessment in new patient evaluations. In ET patients with high-risk disease, aspirin plus either hydroxyurea versus pegylated interferon is the standard first line therapy. Anagrelide is appropriate as an adjunct to therapy or for second line usage. Clinical trial enrollment is imperative to answer outstanding questions regarding safety, tolerability, and efficacy of alternative therapies²⁹.

including JAK2 and telomerase inhibitors, both of which have demonstrated promising early results in the treatment of ET.

Author contributions

Krisztina Gowin: Authored manuscript, literature review

Ruben Mesa: Edits

Both authors agreed to the final content of the manuscript.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Tefferi A, Thiele J, Vardiman JW: **The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.** *Cancer*. 2009; **115**(17): 3842–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Vardiman JW, Thiele J, Arber DA, *et al.*: **The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.** *Blood*. 2009; **114**(5): 937–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kralovics R, Passamonti F, Buser AS, *et al.*: **A gain-of-function mutation of JAK2 in myeloproliferative disorders.** *N Engl J Med*. 2005; **352**(17): 1779–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Levine RL, Wadleigh M, Cools J, *et al.*: **Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.** *Cancer Cell*. 2005; **7**(4): 387–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
- James C, Ugo V, Le Couedic JP, *et al.*: **A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.** *Nature*. 2005; **434**(7037): 1144–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klampfl T, Gisslinger H, Harutyunyan AS, *et al.*: **Somatic mutations of calreticulin in myeloproliferative neoplasms.** *N Engl J Med*. 2013; **369**(25): 2379–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pardanani AD, Levine RL, Lasho T, *et al.*: **MPLS1515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.** *Blood*. 2006; **108**(10): 3472–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pikman Y, Lee BH, Mercher T, *et al.*: **MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.** *PLoS Med*. 2006; **3**(7): e270.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mesa RA, Niblack J, Wadleigh M, *et al.*: **The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.** *Cancer*. 2007; **109**(1): 68–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Emanuel RM, Dueck AC, Geyer HL, *et al.*: **Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.** *J Clin Oncol*. 2012; **30**(33): 4098–103.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Scherber R, Dueck AC, Johansson P, *et al.*: **The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.** *Blood*. 2011; **118**(2): 401–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Barbui T, Barosi G, Birgegard G, *et al.*: **Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.** *J Clin Oncol*. 2011; **29**(6): 761–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Passamonti F, Thiele J, Girodon F, *et al.*: **A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.** *Blood*. 2012; **120**(6): 1197–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Barbui T, Finazzi G, Carobbio A, *et al.*: **Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).** *Blood*. 2012; **120**(26): 5128–33; quiz 5252.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tefferi A: **Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.** *Am J Hematol*. 2013; **88**(6): 507–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Antonoli E, Guglielmelli P, Pancrazzi A, *et al.*: **Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.** *Leukemia*. 2005; **19**(10): 1847–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gangat N, Wassie E, Lasho T, *et al.*: **Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.** *Eur J Haematol*. 2014.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Barbui T, Finazzi G, Falanga A: **Myeloproliferative neoplasms and thrombosis.** *Blood*. 2013; **122**(13): 2176–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Landolfi R, Marchioli R, Kutti J, *et al.*: **Efficacy and safety of low-dose aspirin in polycythemia vera.** *N Engl J Med*. 2004; **350**(2): 114–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cortelazzo S, Finazzi G, Ruggeri M, *et al.*: **Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.** *N Engl J Med*. 1995; **332**(17): 1132–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Steurer M, Gastl G, Jedrzejczak WW, *et al.*: **Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.** *Cancer*. 2004; **101**(10): 2239–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Harrison CN, Campbell PJ, Buck G, *et al.*: **Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.** *N Engl J Med*. 2005; **353**(1): 33–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kiladjian JJ, Cassinat B, Chevret S, *et al.*: **Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.** *Blood*. 2008; **112**(8): 3065–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Quintas-Cardama A, Kantarjian H, Manshouri T, *et al.*: **Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.** *J Clin Oncol*. 2009; **27**(32): 5418–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Silver RT, Vandriss K, Goldman JJ: **Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.** *Blood*. 2011; **117**(24): 6669–72.
[PubMed Abstract](#) | [Publisher Full Text](#)

26. Tefferi A, Elliot MA, Yoon SY, *et al.*: **Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.** *Blood.* 2001; **97**(6): 1896.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Mesa RA, Silverstein MN, Jacobsen SJ, *et al.*: **Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995.** *Am J Hematol.* 1999; **61**(1): 10–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Mesa RA, Verstovsek S, Cervantes F, *et al.*: **Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).** *Leuk Res.* 2007; **31**(6): 737–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Fiskus W, Ganguly S, Kambhampati S, *et al.*: **Role of additional novel therapies in myeloproliferative neoplasms.** *Hematol Oncol Clin North Am.* 2012; **26**(5): 959–80.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 13 October 2014

<https://doi.org/10.5256/f1000research.5723.r6243>

© 2014 Mullally A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ann Mullally

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Nice summary of clinical management of ET.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 October 2014

<https://doi.org/10.5256/f1000research.5723.r6242>

© 2014 Michaelis L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Laura C. Michaelis

Hematologic Malignancies Program, Division of Hematology/Oncology, Medical College of Wisconsin, Froedtert Hospital, Milwaukee, WI, USA

This is a well-written review that addresses some of the key considerations in the diagnosis and treatment of ET. The authors are right to emphasize the importance of a bone marrow biopsy in diagnosis, as it is important to exclude early PMF, which can have a different disease trajectory. In addition, practitioners should also be aware of the disproportionately high rates of splanchnic vein or mesenteric thromboses, which can be a presenting symptom in these patients and should prompt clinicians to search for MPNs.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research